TenQ · fact sheet · filings current to · price as of
Gilead Sciences (GILD)
The business itself is the question here - 19 of 36 checks passed.
Latest close : $151.00, -0.1% on the day; -1.9% from the 52-week high. Refreshed every trading night.
Full analysis: report · all charts. Financial statements are computed from SEC EDGAR XBRL filings, current to . The share price and everything built on it (market cap, multiples, yields, the Value and Trend checks) are refreshed every trading night; this page shows the close of . Not investment advice.
Key figures
| Share price (delayed close) | $151.00 |
| Market cap | $187.2B |
| 52-week range | $108.50 - $153.91 |
| P/E | - |
| P/E, own 11-year median | 14.8x |
| P/S | 6.1x |
| Free cash flow yield | 6.9% |
| Dividend yield | 2.1% |
| Revenue (TTM) | $30.5B |
| Net income (TTM) | $-3.2B |
| Free cash flow (TTM) | $12.9B |
| Gross margin | 65.0% |
| Operating margin | -8.2% |
| Return on equity | -27.4% |
| Revenue growth (1y) | +5.5% |
| Revenue CAGR (3y) | +2.6% |
| Debt / equity | 2.22x |
| Cash & short-term investments | $3.2B |
| Shares outstanding | 1,240m (cover page of the latest filing, 2026-07-31) |
The score: 19 of 36 checks passed
Six chapters, six pass/fail checks each. Five are computed from the filings; Trend is price behaviour, and says so.
Is GILD stock cheap or expensive right now?
Value · 1 of 6 checks passed. Expensive against its own history and its sector (judged on sales - not yet profitable) - you're paying up for what you get. chapter →
Is Gilead Sciences still growing?
Growth · 3 of 6 checks passed. Growing, but with caveats - revenue +5.5% over the last year. chapter →
Does Gilead Sciences make real money?
Quality · 2 of 6 checks passed. Profitability is thin or negative - the growth isn't turning into money yet. chapter →
Can Gilead Sciences survive a bad year?
Health · 2 of 6 checks passed. The balance sheet carries real risk - read the checks before anything else. chapter →
What does Gilead Sciences hand back to shareholders?
Shareholder returns · 5 of 6 checks passed. Owners are paid reliably and affordably, and the share count is not eroding their stake. chapter →
Which way is GILD trending?
Trend analysis · 6 of 6 checks passed. The market agrees: the stock is in a healthy uptrend on every horizon. chapter →
Are insiders buying or selling GILD?
Open-market buys: $0.00 · sells: $21M, across the recent Form 4 filings. detail →
Other pharma and chemicals we cover: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · Procter & Gamble (PG) · Amgen (AMGN) · every company →
Method: figures computed deterministically from SEC EDGAR XBRL (companyfacts, frames, financial-statement-and-notes datasets, Form 4); prices delayed end-of-day. Scores count transparent pass/fail checks. Missing data is shown as missing, never estimated. Last changed . © TenQ - cite with a link to this page.